Transform your drug discovery pipeline with 3D cellular models

Supported by:

Published: 7 July 2025

Share this post

4

Share via

• Facebook
• Like
• Twitter
• Pinterest
• LinkedIn
• Digg
• Del
• Tumblr
• VKontakte
• Print
• Email
• Reddit
• Buffer
• Love This
• Weibo
• Pocket
• Xing
• Odnoklassniki
• WhatsApp
• Meneame
• Blogger
• Amazon
• Yahoo Mail
• Gmail
• AOL
• Newsvine
• HackerNews
• Evernote
• MySpace
• Mail.ru
• Viadeo
• Line
• Flipboard
• Comments
• Yummly
• SMS
• Viber
• Telegram
• Subscribe
• Skype
• Facebook Messenger
• Kakao
• LiveJournal
• Yammer
• Edgar
• Fintel
• Mix
• Instapaper
• Copy Link

This exclusive report, featuring insights from leading pharmaceutical companies, academic institutions, and technology providers, reveals how 3D cellular models are bridging the gap between laboratory research and clinical success. 

What you’ll discover 

• Human-relevant models that work – Explore real-world cases where 3D models accurately predicted clinical outcomes, including studies in cystic fibrosis and cancer that show strong correlations with patient responses.
• Practical implementation strategies – Learn how the industry is solving the complexity vs. throughput challenge and adopting standardisation protocols. Explore technologies that scale 3D models without losing biological relevance.
• Next-generation biomarkers – Understand why traditional biomarkers often fail in 3D systems and discover the novel approaches experts are using for biomarker discovery and validation. Learn how these innovations are helping to bridge the gap between preclinical data and clinical outcomes.
• Safety assessment revolution – Learn how 3D models are capturing species-specific toxicity effects and gaining attention from regulatory agencies. Discover how the industry is working to build confidence with the FDA and others to support broader acceptance of these models.
• Industry collaboration insights – Learn how strategic partnerships are accelerating the adoption of 3D models and how data sharing strategies are advancing the field. Discover the benefits of the International Consortium for Innovation & Quality in Pharmaceutical Development (IQ MPS) approach in driving collaboration and standardisation 

Who should read this report 

• Drug discovery scientists looking to improve predictive models 
• Safety assessment teams seeking human-relevant toxicity testing 
• R&D directors evaluating next-generation technologies 
• Regulatory affairs professionals preparing for 3D model submissions 

Expert roundtable participants 

This report captures insights from a distinguished panel representing: 

• Leading pharmaceutical companies implementing 3D models at scale 

• Academic research institutions pioneering new methodologies 

• Technology providers developing cutting-edge solutions 

• Regulatory experts shaping future guidelines 

The future is here – don’t let your models hold back your breakthroughs 

Access your free copy now!